Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference

New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies delivered via the revolutionary oral mucosal immunotherapy treatment platform, is proud to announce that it was selected to receive the Best Private Company Presentation Award at the 9th Annual BioNJ BioPartnering Conference.

Intrommune Therapeutics CEO, Michael Nelson, presented at the 9th Annual BioNJ BioPartnering Conference on May 8th at the Palace at Somerset Park in Somerset, NJ. The event was co-sponsored by JP Morgan and J&J Innovation. BioNJ, the life sciences trade association of NJ, convened over 550 life partnering professionals for a day of company presentations, partnering meetings, plenary sessions and exhibits. Intrommune Therapeutics was selected as one of 32 conference company presenters following a competitive selection process that included company application submissions from the northeast to mid-Atlantic regions.

Michael Nelson, JD, Co-Founder and CEO of Intrommune Therapeutics, said, “We are very pleased to have received this award, which acknowledges Intrommune Therapeutics’ commitment to bringing vital treatments to patients in need.”

"This year’s company presentation awards have been exciting, featuring the most competitive field of strong leadership teams with cutting-edge innovations we have seen at BioNJ,” said John Pennett of EisnerAmper, LLP after he presented the award. “I am proud to see Intrommune Therapeutics chosen as the 2019 winner. This award recognizes their hard work and innovative technology for those who suffer from peanut and other food allergies.”

Intrommune’s lead product, INT301, is being developed for the treatment of peanut allergies. INT301’s unique formulation is designed to desensitize an individual with peanut allergy and is delivered via a fully-functional toothpaste, protecting them in the event of accidental ingestion. Approximately 6 million people, including an estimated 1.7 million children, have peanut allergy in the U.S. If approved, INT301 has the potential to be the first allergy immunotherapy treatment that easily integrates into a person’s daily routine as both first-line and long-term maintenance therapy for peanut allergy.

The OMIT platform is expected to improve the delivery of allergy immunotherapy by increasing the precision of treatment delivery and promoting treatment adherence. OMIT delivers biologically active compounds to the areas of the oral mucosa that have the highest likelihood of initiating allergy desensitization. Targeted delivery of medication is expected to decrease the rate of side effects linked to swallowing food allergy proteins, including eosinophilic esophagitis, gastrointestinal discomfort and potentially life-threatening anaphylaxis that requires the use of emergency epinephrine. 

About Oral Mucosal Immunotherapy
Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and support of reliable, long-term adherence.

About Intrommune Therapeutics
Intrommune, dedicated to improving and protecting the lives of people with food allergy, is developing food allergy therapies delivered via the revolutionary oral mucosal immunotherapy (OMIT) treatment platform. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 26 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. There is no FDA-approved treatment for peanut allergy or any other food allergy.

For more information on Intrommune Therapeutics, please follow the link to

Cautionary Statement Regarding Forward Looking Statements

This release may contain "forward-looking statements." Forward-looking statements are identified by certain words or phrases such as "may," "will," "aim," "will likely result," "believe," "expect," "will continue," "anticipate," "estimate," "intend," "plan," "contemplate," "seek to," "future," "objective," "goal," "project," "should," "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect the company's current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction.


Contact Data